LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Last trade$39.66
Day change-$3.33 (-7.75%)
Day range$39.02 – $43.87
Volume204,298
Market cap$1.39B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.39B
Price / earnings
—
Price / book
3.33×
Price / sales
—
EV / sales
—
EV / EBITDA
-7.74×
Profitability
Earnings per share
-$4.36
Return on assets
-31.14%
Return on equity
-33.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.78×
Quick ratio
14.78×
Cash ratio
7.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$143.82M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LBRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$10.98M
$9.77M
$7.46M
$5.39M
$2.83M
Research and development
$51.52M
$44.15M
$14.65M
$8.48M
$2.42M
Total operating expenses
$62.5M
$53.92M
$22.1M
$13.87M
$5.25M
Operating income
-$62.5M
-$53.92M
-$22.1M
-$13.87M
-$5.25M
Interest expense
$0
$0
$0
$0
$0
Income before taxes
-$59.07M
-$51.6M
-$19.05M
-$11.47M
-$3.56M
Income taxes
$0
$0
$0
$1K
$0
Net income
-$59.07M
-$51.6M
-$19.05M
-$11.47M
-$3.56M
Net income attributable to common shareholders
-$59.07M
-$51.6M
-$19.05M
-$11.47M
-$3.56M
EBITDA
-$62.37M
-$53.82M
-$22.02M
-$13.79M
-$5.17M
Basic earnings per share
-$1.79
-$1.71
-$0.67
-$0.45
-$0.61
Diluted earnings per share
-$1.79
-$1.71
-$0.67
-$0.45
-$0.61
Recent news
Company coverage with links to the original publishers.
LB Pharmaceuticals Inc announced equity awards to newly appointed Chief Medical Officer Dr. Susan G. Kozauer and Chief Financial Officer Joseph Miller. Each executive received options to purchase 200,000 shares at an exercise price of $37.22, vesting over 4 years with a 10-year term. The grants were made as inducement awards under Nasdaq Listing Rule 5635(c)(4).
LB Pharmaceuticals announced that its Phase 3 NOVA-2 trial of LB-102 for schizophrenia will report topline results in the first half of 2027, ahead of previous guidance. The accelerated timeline reflects faster-than-expected enrollment across 25 U.S. sites. The company maintains sufficient cash runway through Q2 2029 to fund multiple clinical readouts, including Phase 2 trials in bipolar depression and adjunctive MDD.
LB Pharmaceuticals Inc (Nasdaq: LBRX) announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. As an inducement to join the company, Zergebel received an equity award of options to purchase 75,000 shares at an exercise price of $32.95 per share, vesting over 4 years. The company continues advancing its lead candidate LB-102, a novel antipsychotic in Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression.
Five psychedelic biotech companies are advancing toward Phase 3 trials for treating depression and anxiety disorders. Helus Pharma reported positive Phase 2a results for SPL026 in major depressive disorder published in Nature Medicine. AtaiBeckley, Definium Therapeutics, GH Research, and LB Pharmaceuticals are all progressing late-stage clinical programs with multiple Phase 3 readouts expected in 2026, signaling the sector's maturation toward regulatory approval.
LB Pharmaceuticals Inc (LBRX) announced a $100 million private placement of common stock and pre-funded warrants at $21.17 per share from institutional investors. The company plans to use proceeds to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, with closing expected on February 6, 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.